MedPath

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Phase 2
Terminated
Conditions
Colorectal Cancer
Interventions
Drug: SI-B001
Drug: FOLFIRI Protocol
Drug: Irinotecan
Drug: FOLFOX Protocol
Registration Number
NCT05039944
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Brief Summary

This multi-center, open label Phase II clinical study is performed in patients with unresectable or metastatic malignant tumors of the digestive system (colorectal cancer, gastric cancer). This study is investigating the safety and efficacy of SI-B001 at monotherapy or optimal combination dose with chemotherapy in patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
7
Inclusion Criteria

  1. Male or female, age ≥18;

  2. Expected survival time ≥3 months;

  3. Patients with unresectable or metastatic colorectal cancer or gastric cancer confirmed by histology or pathology:

    Cohort_A: Patients with unresectable or metastatic gastric cancer, HER2-negative, without standard treatment.

    Cohort_B: Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer, failure of conventional chemotherapy combined with EGFR mab, and withdrawal of EGFR mab for less than 3 months.

    Cohort_C: MSS KRASwt BRAFwt patients with unresectable or metastatic colorectal cancer who have failed multiline conventional chemotherapy (without EGFR monoclonal antibody therapy).

    Cohort_D: MSI-H KRASwt BRAFwt patients with unresectable or metastatic colorectal cancer and previous first - or second-line treatment failure with anti-PD-1 (L1) mab (excluding EGFR mab).

    Cohort_E: MSI-H KRASwt BRAFwt patients with unresectable or metastatic colorectal cancer who have previously failed first-line anti-PD-1 (L1) mab therapy.

    Cohort_F: MSS KRASwt BRAFwt patients with unresectable or metastatic colorectal cancer who have failed standard therapy with first-line oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab.

  4. No previous anti-EGFR antibody therapy (excluding Cohort_B);

  5. Agree to provide 4 specimens (thickness 5μm) of tumor tissue specimens (non-stained sections (anti-removal)) archiving from primary or metastatic tumors;agree to provide 6 unstained sections surgical specimens (anti-removal, thickness 10μm) or fresh tissue samples;

  6. There must be at least one measurable lesion conforming to the RECIST V1.1 definition;

  7. Cohort_A, B, C fitness scores ≤2, Cohort_D, E, F fitness scores ≤1;

  8. Toxicity of previous antitumor therapy has been restored to ≤1 as defined by NCI-CTCAE V5.0 (except for toxicity that the researchers judge to be of no safety risk, such as hair loss, grade 2 peripheral neurotoxicity, and stabilized hypothyroidism after hormone replacement therapy);

  9. Organ function levels must meet the following requirements and meet the following standards:

    A) Bone marrow function: absolute value of neutrophil count (ANC) ≥1.5×109/L, platelet count ≥100×109/L (platelet count ≥75×109/L in Patients with Cohort_A, B and C), hemoglobin ≥90 g/L (hemoglobin ≥85 g/L in patients with Cohort_A, B and C); B) Liver function: Total bilirubin TBIL≤1.5×ULN (total bilirubin TBIL≤ 3×ULN in Gilbert's syndrome, liver cancer or liver metastases); AST and ALT ≤2.5×ULN in patients without liver metastasis; AST and ALT ≤5.0×ULN in patients with liver metastasis; C) Renal function: Creatinine (Cr) ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to Cockcroft and Gault formula); D) Urine routine / 24-hour protein quantification: qualitative urine protein ≤1+ (if qualitative urine protein ≥2+, 24 hours < 1g can be included); E) Cardiac function: left ventricular ejection fraction ≥50%; F) Coagulation function: International standardized ratio (INR) ≤1.5×ULN, and activated partial thrombin time (APTT) ≤1.5×ULN;

  10. Eligible patients (male and female) who are fertile must agree to use a reliable contraceptive method (hormonal or barrier method or abstinence, etc.) with their partner during the trial and for at least 6 months after the last medication;Women of childbearing age must have a negative blood or urine pregnancy test within 7 days prior to the first use of the study drug.

Read More
Exclusion Criteria

  1. Colorectal cancer patients with HER2 positive (immunohistochemical +++, or immunohistochemical ++ with FISH amplification);

  2. Have received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor therapy within 4 weeks prior to the first use of the study drug, except the following:

    Oral fluorouracil and small molecule targeted drugs are 2 weeks before the first administration of the study drug or within the 5 half-lives of the drug (whichever is longer); The traditional Chinese medicines with anti-tumor indications were within 2 weeks before the first use of the study drug;

  3. Received an unmarketed clinical investigational drug or treatment within 4 weeks prior to the first use of the investigational drug;

  4. Has undergone major organ surgery (excluding needle biopsy, tracheotomy, gastrostomy, etc.) or has significant trauma within 4 weeks before the first use of study drugs, or needs to undergo elective surgery during the trial;

  5. Previous recipients of allogeneic hematopoietic stem cell transplantation or organ transplantation;

  6. A history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

    Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade iii atrioventricular block, etc.

    In the resting state, QT interval was prolonged (QTc > 450 msec in men or QTc > 470 msec in women); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 or higher cardio-cerebrovascular events within 6 months prior to the first administration; New York Heart Association (NYHA) heart function grade ≥II heart failure;

  7. Active autoimmune and inflammatory diseases, such as systemic lupus erythematosus, inflammatory bowel disease, etc., except type I diabetes, hypothyroidism that can be controlled only with replacement therapy, and skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis);

  8. A history of other malignant tumors within 3 years prior to the first administration, with no signs of recurrence and metastasis;

  9. Poorly controlled hypertension (systolic blood pressure & GT;150 mmHg or diastolic pressure &gt;100 mmHg);

  10. Pulmonary disease defined as grade 3 or higher according to CTCAE V5.0;Patients with past or present interstitial lung disease (ILD);

  11. Cerebral parenchymal or meningeal metastases with clinical symptoms are not suitable for inclusion by the investigator;

  12. Had ≥ grade 3 infusion-related reactions during prior anti-EGFR antibody therapy (Cohort_B only);

  13. There are known allergic contraindications to any excipients of SI-B001 and chemotherapeutic agents selected in this study;

  14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number > 104) or hepatitis C virus infection (HCV-RNA > center detection lower limit);

  15. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.;

  16. Pregnant or lactating women;

  17. Persons with mental disorders or poor compliance;

  18. The investigator considers that the subject has a history of other serious systemic diseases or other reasons and is not suitable to participate in this clinical study.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SI-B001 combined with FOLFIRI or FOLFOX_EFOLFIRI ProtocolPatients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001 combined with FOLFIRI or FOLFOX_EFOLFOX ProtocolPatients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001_ASI-B001Patients with unresectable or metastatic gastric cancer, HER2-negative and without standard treatment were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001_BSI-B001Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed conventional chemotherapy combined with EGFR mab were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001_CSI-B001Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed multiple lines of conventional chemotherapy (excluding EGFR monoclonal antibody) were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001 combined with irinetecan_DSI-B001Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed to receive anti-PD-1 (L1) mab (excluding EGFR mab) in the first or second line were treated with SI-B001 in combination with irinetecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001 combined with FOLFIRI or FOLFOX_ESI-B001Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001 combined with irinetecan_FSI-B001Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed standard first-line treatment containing oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab were treated with SI-B001 plus irinotecan in the second-line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001 combined with irinetecan_DIrinotecanPatients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed to receive anti-PD-1 (L1) mab (excluding EGFR mab) in the first or second line were treated with SI-B001 in combination with irinetecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
SI-B001 combined with irinetecan_FIrinotecanPatients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed standard first-line treatment containing oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab were treated with SI-B001 plus irinotecan in the second-line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
Primary Outcome Measures
NameTimeMethod
Optimal combination dose (only IIa)Up to approximately 24 months

Optimal combination dose of SI-B001 with chemothreapy (only IIa)

ORRUp to approximately 24 months

Objective Response Rate

Secondary Outcome Measures
NameTimeMethod
DORUp to approximately 24 months

Duration of Response

TEAEUp to approximately 24 months

Treatment Emergent Adverse Events

CmaxUp to approximately 24 months

Maximum serum concentration

TmaxUp to approximately 24 months

Time to maximum serum concentration

CtroughUp to approximately 24 months

Minimum serum concentration

OSUp to approximately 24 months

Overall Survival

PFSUp to approximately 24 months

Progression-free Survival

DCRUp to approximately 24 months

Disease Control Rate

ADAUp to approximately 24 months

anti-SI-B001 antibody

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy